Noncoding RNAs as a novel approach to target retinopathy of prematurity

Bibliographic Details
Title: Noncoding RNAs as a novel approach to target retinopathy of prematurity
Authors: Hyunjong Kim, Jaesub Kim, Juhee Ryu
Source: Frontiers in Pharmacology, Vol 13 (2022)
Publisher Information: Frontiers Media S.A., 2022.
Publication Year: 2022
Collection: LCC:Therapeutics. Pharmacology
Subject Terms: microRNA, long noncoding RNA, circular RNA, retinopathy of prematurity, retinal vascular disease, noncoding RNA, Therapeutics. Pharmacology, RM1-950
More Details: Retinopathy of prematurity (ROP), a vascular disease characterized by abnormal vessel development in the retina, has become a primary cause of blindness in children around the world. ROP can be developed during two different phases: vessel loss and vessel proliferation. Once preterm infants with immature retinal vessel growth are exposed to high level of oxygen inside the incubator, vessel loss can occur. When infants are exposed to room air, they may experience the proliferation of vessels in the retina. Although multiple factors are reported to be involved in the pathogenesis of ROP, including vaso-endothelial growth factors (VEGFs) and hypoxia-inducible factors, the pathogenesis of ROP is not completely understood. Although laser therapy and pharmacologic agents, such as anti-VEGF agents, have been commonly used to treat ROP, the incidence of ROP is rapidly rising. Given that current therapies can be invasive and long-term effects are not fully known, the search for novel therapeutic targets with less destructive properties needs to be considered. Within the last decade, the field of noncoding RNA therapy has shown potential as next-generation therapy to treat diverse diseases. In this review, we introduce various noncoding RNAs regulating ROP and discuss their role as potential therapeutic targets in ROP.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 1663-9812
Relation: https://www.frontiersin.org/articles/10.3389/fphar.2022.1033341/full; https://doaj.org/toc/1663-9812
DOI: 10.3389/fphar.2022.1033341
Access URL: https://doaj.org/article/d889086d7bcd4d37af67c4e37b77d88c
Accession Number: edsdoj.889086d7bcd4d37af67c4e37b77d88c
Database: Directory of Open Access Journals
More Details
ISSN:16639812
DOI:10.3389/fphar.2022.1033341
Published in:Frontiers in Pharmacology
Language:English